ABL1 and lung carcinoma: For example, the oncogenic ABL1 and 2 kinases, shown to be overexpressed or hyperactivated in NSCLC [85,86,87,88] and involved in tumor growth and metastasization in experimental models of lung cancer [27,87,88], have been recently demonstrated to act in part through the activation of TAZ and β-catenin by inhibiting their binding to β-TrCP, thus increasing their stability.